Fulltext

Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

Kavanagh D 1 , Ardissino G 2 , Brocklebank V 3 , Bouwmeester RN 4 , Bagga A 5 , Ter Heine R 6 Show all authors , Johnson S 7 , Licht C 8 , Ma ALT 9 , Noris M 10 , Praga M 11 , Rondeau E 12 , Sinha A 5 , Smith RJH 13 , Sheerin NS 3 , Trimarchi H 14 , Wetzels JFM 15 , Vivarelli M 16 , Van de Kar NCAJ 4 , Greenbaum LA 17 , Forum Participants

Affiliations 

  • 1 National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address: david.kavanagh@ncl.ac.uk
  • 2 Center for Hemolytic Uremic Syndrome (HUS) Prevention, Pediatric Nephrology, Dialysis and Transplantation Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
  • 3 National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
  • 4 Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, The Netherlands
  • 5 Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
  • 6 Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands
  • 7 National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Great North Children's Hospital, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
  • 8 Division of Nephrology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
  • 9 Paediatric Nephrology Centre, Hong Kong Children's Hospital, Hong Kong, China; Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
  • 10 Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Italy
  • 11 Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain; Medicine Department, Universidad Complutense de Madrid, Madrid, Spain
  • 12 Intensive Care Nephrology and Transplantation Department, Assistance Publique des Hôpitaux de Paris (AP-HP) - Sorbonne Université, Paris, France
  • 13 Molecular Otolaryngology and Renal Research Laboratories, The University of Iowa, Iowa City, Iowa, USA
  • 14 Nephrology Service, Hospital Britanico de Buenos Aires, Buenos Aires, Argentina
  • 15 Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
  • 16 Division of Nephrology, Laboratory of Nephrology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
  • 17 Division of Pediatric Nephrology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: lgreen6@emory.edu
Kidney Int, 2024 Dec;106(6):1038-1050.
PMID: 39395628 DOI: 10.1016/j.kint.2024.09.012

Abstract

Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications